Abeona therapeutics® completes pz-cel biologics license application resubmission to u.s. food and drug administration

Cleveland, oct. 29, 2024 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today announced that the company has resubmitted its biologics license application (bla) to the u.s. food and drug administration (fda or agency) for prademagene zamikeracel (pz-cel), its investigational autologous cell-based gene therapy, as a potential new treatment for patients with recessive dystrophic epidermolysis bullosa (rdeb).
ABEO Ratings Summary
ABEO Quant Ranking